Back to Authors

Savica, Rodolfo

https://orcid.org/0000-0002-2543-0627

Mayo Clinic

Mayo Clinic

Citations 250

Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease
Gavrielatos, Marios , Heckman, Michael G. , Blumenfeld, Sophia G. , Hou, Xu , Koga, Shunsuke , Murray, Melissa E., Kasanuki, Koji , Ono, Daisuke , Fiesel, Fabienne C. , Uitti, Ryan J. , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Ertekin‐Taner, Nilüfer , Dalgard, Clifton L., Savica, Rodolfo , Graff‐Radford, Jonathan , Petersen, Ronald C. , Reichard, R. Ross , Graff‐Radford, Neill R., Ferman, Tanis J. , Boeve, Bradley F., Wszolek, Zbigniew K., Mignot, Emmanuel, Scholz, Sonja W. , Ross, Owen A. , Koga, Shunsuke , Fiesel, Fabienne C , Ramanan, Vijay K , Kantarci, Kejal , Savica, Rodolfo , Graff-Radford, Jonathan , Petersen, Ronald C , Gan-Or, Ziv , Scholz, Sonja W , Dickson, Dennis W , Ross, Owen A , Jack, Clifford R , Heckman, Michael G , Ferman, Tanis J , Soto‐Beasley, Alexandra I. , Hou, Xu , Murray, Melissa E. , Botha, Hugo , Ramanan, Vijay K. , Gibbs, J. Raphael , Traynor, Bryan J. , Graff‐Radford, Neill R. , Boeve, Bradley F. , Springer, Wolfdieter , Gan‐Or, Ziv , Dickson, Dennis W.

Annals of Neurology | November 7, 2025 | Volume: 99 | Issue: 2 | Pages: 492-501

10.1002/ana.78075 Get It

Objective Lewy body disease (LBD) is a complex neurodegenerative disorder characterized by the accumulation of misfolded α‐synuclein in the brain. Neuroinflammation has long been implicated in LBD pathogenesis, and recent genetic studies in Parkinson's disease (a clinical manifestation of LBD) have shown consistent association with the human leukocyte antigen (HLA) gene complex. Here, we assessed whether variation in HLA alleles influences neuropathological burden in a neuropathologically‐defined series of LBD cases. Methods We conducted a comprehensive analysis of HLA allelic variants in a cohort of 539 LBD cases of European descent from the Mayo Clinic brain bank. High‐resolution whole‐genome sequencing was used, and the HLA alleles of each sample were called using the HLA*LA tool and assessed for association with neuropathological outcomes. Results Our analysis identified 1 significant ( P < 3.43 × 10 −5 ) and 4 suggestive ( P < 0.001) associations between certain HLA alleles and specific neuropathological outcomes in LBD, suggesting a potential role for HLA‐mediated immune mechanisms in disease progression and subtype differentiation. Specifically, HLA‐DPB1*06:01 was significantly associated with lower Lewy body counts in the parahippocampal gyrus ( P = 3.30 × 10 −5 ), with weaker and suggestive associations observed in the middle frontal ( P = 1.80 × 10 −4 ) and inferior parietal gyrus ( P = 6.33 × 10 −4 ). Additionally, although only suggestive, HLA‐DRB1*11:01 correlated with a lower Thal amyloid phase ( P = 1.56 x 10 −4 ), and HLA‐B*15:01 correlated with an increased risk of diffuse LBD ( P = 7.58 x 10 −4 ). Interpretation This study provides a detailed evaluation of the relationship between HLA alleles and LBD pathology, highlighting the importance of immune‐related genetic factors in the etiology of LBD. ANN NEUROL 2026;99:492–501
Dysphagia Is Associated with Incident Non‐Motor Symptoms in Parkinson's Disease
Rehman, Muhammad Abdul , Savica, Rodolfo , Varma, Revati , Bailey, Kent R. , Bharucha, Adil E. , Abdul Rehman, Muhammad , Bharucha, A E , Vierkant, Robert A.

Movement Disorders Clinical Practice | August 20, 2025 | Volume: 12 | Issue: 11 | Pages: 1909-1924

10.1002/mdc3.70297 Get It

Abstract Background Up to 80% of persons with Parkinson's disease (PwPD) have dysphagia. However, existing studies are based on small cohorts and the relationship between dysphagia and other motor and nonmotor symptoms (NMS) remains incompletely understood. Objectives To evaluate the relationship between motor and NMS in PwPD with vs without dysphagia. Methods Among 20,365 PwPD in the Michael J. Fox Foundation database who completed ≥2 NMS surveys, 12,678 (62%) reported dysphagia on ≥1 survey. We examined associations between dysphagia and: (1) self‐reported motor symptoms (UPDRS Part II), other NMS, quality of life (QoL), comorbidity score, depression, and daily activities at baseline; and (2) development of new NMS. Results Compared to PwPD without dysphagia, those with dysphagia were more likely to have had PD for >5 years, more severe motor and NMS, higher comorbidity scores, and a greater impairment in daily activities ( P < 0.001). The prevalence of dysphagia increased with the severity of motor symptoms at the index survey ( P < 0.001). At baseline, all NMS were significantly associated with dysphagia. Compared to PwPD who did not have dysphagia, PwPD with dysphagia were at increased risk of developing every NMS, even after adjusting for ages at PD diagnosis and index survey, sex, cognitive impairment, UPDRS, NMS and comorbidity scores. For most NMS, the risk of progression was greater in those with cognitive impairment or elevated NMS scores. Conclusions Dysphagia in PwPD is associated with more severe motor and non‐motor symptoms, reduced QoL, and an increased risk of future NMS.
Psychosis in early onset Parkinson's disease: A retrospective cohort study in southeast Minnesota
Derhab, Mohamed , Mullan, Aidan F. , Turcano, Pierpaolo , Camerucci, Emanuele, Piat, Capucine , Ghoniem, Khaled , Bower, James H., Savica, Rodolfo , Dehnavi, Ali Zare, Savica, Rodolfo , Mullan, Aidan , Camerucci, Emanuele , Dehnavi, Ali Zare

Journal of Parkinson’s Disease | July 1, 2025 | Volume: 15 | Issue: 6 | Pages: 1078-1085

10.1177/1877718x251354978 Get It

Background Early onset Parkinson's disease (EOPD), defined as Parkinson's disease (PD) diagnosed before age 50, often presents unique challenges compared to late-onset PD, particularly with regard to non-motor symptoms. Psychosis in EOPD is associated with increased functional impairment and may lead to a higher mortality risk. Objective Our study is aimed to determine the prevalence of psychosis in EOPD patients and its impact on all-cause mortality, along with examining the effects of antipsychotic medications and Selective Serotonin Reuptake Inhibitors (SSRIs) on mortality in EOPD patients. Methods Our retrospective cohort included EOPD patients diagnosed between 1990 and 2022 at Mayo Clinic, Rochester, Minnesota. Psychosis was defined using the National Institute of Neurological Disorders and Stroke/the National Institute of Mental Health (NINDS/NIMH) Work Group criteria. Cox proportional hazards models were used to analyze the association of psychosis and medications with mortality. Results Of 829 patients with EOPD, 158 (19.1%) developed psychosis at a median of 12.1 years after PD motor symptom onset. Psychosis was significantly associated with increased mortality in unadjusted (HR = 4.31, 95% CI: 2.59–7.18, p < 0.001) and adjusted (HR = 3.55, 95% CI: 2.10–6.01, p < 0.001) models. No significant difference in mortality risk was observed between patients treated with antipsychotics or SSRIs versus those who were not. Conclusions Psychosis is a possible complication in EOPD and is associated with a significant increase in all-cause mortality. The use of antipsychotics and SSRIs did not significantly alter the mortality risk in these patients. Further research is needed to understand the mechanisms driving this association and to develop tailored interventions.
Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study
Diaz‐Galvan, Patricia , Przybelski, Scott A. , Lesnick, Timothy G. , Nguyen, Aivi T. , Reichard, Ross R., Ono, Daisuke , Schwarz, Christopher G., Gunter, Jeffrey L. , Lowe, Val J. , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , Jones, David, Day, Gregory S. , Graff‐Radford, Neill, Kremers, Walter K. , Petersen, Ronald C., Jack, Clifford R. , Ferman, Tanis J. , Boeve, Bradley F., Kantarci, Kejal , Gunter, Jeffrey, Savica, Rodolfo , Graff-Radford, Jonathan , St Louis, E K , Kantarci, Kejal , Jack, Clifford R , Day, Gregory S , Ferman, Tanis J , Nguyen, Aivi T , Diaz-Galvan, Patricia , Kremers, Walter K , Murray, Melissa E. , Dickson, Dennis W. , Senjem, Matthew L. , Schwarz, Christopher G. , Ramanan, Vijay K. , Jones, David, Botha, Hugo , Louis, Erik K. St. , Knopman, David S. , Graff‐Radford, Neill, Petersen, Ronald C. , Boeve, Bradley F.

Movement Disorders | June 23, 2025 | Volume: 40 | Issue: 10 | Pages: 2129-2138

10.1002/mds.30265 Get It

Abstract Objective To compare iron deposition in the substantia nigra (SN) as measured with quantitative susceptibility mapping (QSM) on antemortem magnetic resonance imaging (MRI) between individuals with and without Lewy‐related pathology at autopsy. Methods We performed a retrospective cohort study including 54 participants who underwent autopsy and antemortem MRI with QSM. Cases were classified as Lewy body disease (LBD)‐present (n = 13) if they had Lewy‐related pathology and LBD‐absent (n = 41) if they did not have Lewy‐related pathology. QSM was calculated for the whole SN and the two subregions: pars compacta (SNc) and pars reticulata (SNr). Nonparametric Wilcoxon rank‐sum tests were used to compare SN QSM values between LBD‐present and LBD‐absent cases. Area under the receiver operating characteristic (ROC) curve (AUC) analyses tested the accuracy of SN QSM values to distinguish the two groups. Associations of QSM values in the SN and its subregions with clinical features were tested with Spearman's correlations. Results The LBD‐present group had higher QSM values in the SNc ( P = 0.008) than the LBD‐absent group with no differences in SNr. QSM values of the SNc distinguished LBD‐present and LBD‐absent cases with good accuracy (AUC = 0.74) and correlated with the presence of parkinsonism and parkinsonism severity. Conclusions This study provides neuropathological confirmation of the utility of SNc QSM as an in vivo biomarker of Lewy‐related pathology. Imaging evidence of abnormal iron deposition in the SNc could potentially serve as a biomarker for inclusion in emerging research frameworks aimed at defining individuals with LBD based on their biological characteristics. Ultimately, this could facilitate more precise diagnoses and guide treatment strategies in LBD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Constipation in a Large Online Cohort of Persons with Parkinson's Disease
Bharucha, Adil E. , Ghafouri, Mohammad , Varma, Revati , Rehman, Muhammad Abdul , Bailey, Kent R. , Bower, James H., Savica, Rodolfo , Abdul Rehman, Muhammad , Savica, Rodolfo , Vierkant, Robert A.

Movement Disorders Clinical Practice | June 20, 2025 | Volume: 12 | Issue: 12 | Pages: 2232-2246

10.1002/mdc3.70168 Get It

Abstract Background Small studies suggest that constipation is a common symptom associated with a worse prognosis in patients with Parkinson's disease (PD). Objectives The aim was to compare the association between constipation, motor, and other non‐motor symptoms (NMS) in PD patients at baseline and in future. Methods Using the Fox Insight database, we compared baseline characteristics, risk of progressive motor symptoms, and incidence of NMS between PD patients with versus without constipation. Results Of 20,352 participants, 16,611 (82%) reported infrequent bowel movements and/or excessive straining, 15,594 (77%) had incomplete evacuation, and 14,165 (70%) reported both symptoms. Patients with constipation were generally older, white, women, had PD >5 years, and had higher NMS and comorbidity scores ( P < 0.001). Constipation was significantly associated with worse motor symptoms and most NMS , especially fecal incontinence (odds ratio [ OR] = 1.65; 95% confidence interval [CI], 1.49–1.82), dysphagia ( OR = 1.20; 95% CI = 1.12–1.29), talking/moving during sleep ( OR = 1.39; 95% CI = 1.30–1.48), and urinary urgency ( OR = 1.23; 95% CI = 1.16–1.32). Constipation was associated with a small, but statistically significant increased risk of some progressive motor symptoms. At a mean median follow‐up of 2.8 years, constipation was associated with an increased risk of incident gastrointestinal, autonomic, neuropsychiatric, sleep‐related, sensory NMS , such as dysphagia (hazard ratio [ HR] = 1.43; 95% CI = 1.35–1.51), fecal incontinence ( HR = 1.87; 95% CI = 1.74–2.01), falls ( HR = 1.44; 95% CI = 1.35–1.52), hallucinations ( HR = 1.65; 95% CI = 1.52–1.79), cognitive impairment ( HR = 1.38; 95% CI = 1.30–1.47), and talking/moving during sleep ( HR = 1.65; 95% CI = 1.55–1.75). Conclusions Constipation is a common symptom associated with severity of motor and other NMS and portends a worse prognosis in persons with PD.
Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer’s disease
Yang, Stephanie , Lin, Andrew A. , Shen, Hanfei , Pappalardo, Laura W., Spychalski, Griffin B. , Forsberg, Leah K. , Grant, Kiera M., Savica, Rodolfo , Reichard, R. Ross , McLean, Pamela J. , Yang, Stephanie J , Jones, David T , Dickson, Dennis W , Reichard, R Ross , Nguyen, Aivi T , Boeve, Brad , McLean, Pamela J , Rosario, Jean G. , Forsberg, Leah K., Grant, Kiera M., Buser, Joshua R. , O’Bryant, Sid, Jones, David T., Dickson, Dennis W. , Nguyen, Aivi T. , Meaney, David F. , Boeve, Bradley F. , Issadore, David

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.06.656900 Get It

Abstract INTRODUCTION Robust plasma-based biomarkers to distinguish Lewy body disease (LBD) and Alzheimer’s disease (AD) are currently lacking. We applied track-etch magnetic nanopore (TENPO) sorting for enrichment of brain-derived extracellular vesicle (EV) signatures as potential biomarkers to address this gap. METHODS We analyzed plasma from 137 autopsy-confirmed patients [30 LBD, 31 AD, 30 AD/LBD, 19 AD with amygdala Lewy bodies (AD/ALB), and 27 controls], sequencing miRNAs from TENPO-isolated GluR2-positive (neuron-enriched) and GLAST-positive (astrocyte-enriched) EVs, and measuring plasma proteins (Aβ40, Aβ42, tau, p-Tau181, p-Tau231) via SIMOA. RESULTS We identified 16 GluR2+, 8 GLAST+, and 4 protein biomarkers with differential expression (false discovery rate-corrected P value < .1) between LBD and AD. A multimodal 15-feature panel classified LBD versus AD with 10-fold cross-validated accuracy = 0.95 and area under the curve (AUC) = 0.96. DISCUSSION Brain-derived EVs offer accurate and accessible miRNA biomarkers for the differential diagnosis of LBD and AD.
Evaluating the Homogeneity of the PSP ‐ RS Syndrome beyond Core Features
Kumar, Mahesh , Brewer, Benjamin, Ali, Farwa , Clark, Heather M. , Stierwalt, Julie A. G., Stephens, Yehkyoung C. , Savica, Rodolfo , Whitwell, Jennifer L. , Josephs, Keith A. , Stierwalt, Julie, Whitwell, Jennifer , Josephs, Keith A , Clark, Heather M , Brewer, Benjamin C. , Dickson, Dennis W.

Movement Disorders Clinical Practice | May 19, 2025 | Volume: 12 | Issue: 10 | Pages: 1560-1570

10.1002/mdc3.70134 Get It

Abstract Background Classic progressive supranuclear palsy RS syndrome (PSP‐RS) is characterized by early postural instability/falls and vertical supranuclear gaze palsy, although other signs/symptoms can occur, for example, axial rigidity, bradykinesia, and cognitive dysfunction. The Movement Disorders Society‐PSP (MDS‐PSP) criteria consider probable PSP‐RS a homogenous syndrome, but this has not been tested. Objectives We aim to investigate relationships between signs/symptoms of PSP‐RS beyond its core features and determine whether PSP‐RS is a homogeneous syndrome. Methods 118 participants who met MDS‐PSP criteria for probable PSP‐RS were analyzed. All participants received an independent clinical diagnosis based on clinical judgment. We first performed a Network Analysis using qgraph with Spearman's correlation to quantify relationships between 16 signs/symptoms followed by a k‐means clustering analysis using the same signs/symptoms to identify possible heterogeneity of the PSP‐RS designation. Results Five network clusters were identified, reflecting: (1) tremor, (2) sensitivity to bright light, (3) oculomotor function, (4) cognition, and (5) akinetic‐rigidity‐praxis. Worse akinetic‐rigidity was associated with better oculomotor function, but worse cognition. Cluster analysis revealed two clusters. Cluster I ( n = 89) had more severe clinical features than Cluster II ( n = 29). Cluster II had a higher frequency of participants (37.9%) clinically judged as not PSP‐RS: these participants were less likely to have PSP pathology on autopsy ( P = 0.03). Conclusions Some signs/symptoms of PSP‐RS strongly associate and are more likely to co‐occur. PSP‐RS, as defined by the MDS‐PSP criteria includes a subset of participants not clinically judged as PSP‐RS who are less likely to have PSP pathology.
Proximity to Golf Courses and Risk of Parkinson Disease
Krzyzanowski, Brittany , Dorsey, E. Ray , Chirag, Sai Shivani, Turcano, Pierpaolo , Camerucci, Emanuele , Bower, James H., Savica, Rodolfo , Mullan, Aidan F.

JAMA Network Open | May 8, 2025 | Volume: 8 | Issue: 5 | Pages: e259198

10.1001/jamanetworkopen.2025.9198 Get It

Importance The role of pesticide exposure from golf courses in Parkinson disease (PD) risk remains unclear. Objective To assess whether proximity to golf courses is associated with increased PD risk and to use information on groundwater vulnerability and municipal well locations to investigate drinking water contamination as a potential route of exposure. Design, Setting, and Participants This case-control study included patients with incident PD and matched controls from the Rochester Epidemiology Project from 1991 to 2015. Data were analyzed between June and August 2024. Exposures Distance to golf courses, living in water service areas with a golf course, living in water service areas in vulnerable groundwater regions, living in water service areas with shallow municipal wells, and living in water service areas with a municipal well on a golf course. Main Outcome and Measures Risk of incident PD. All models adjusted for age, sex, race and ethnicity, year of index, median household income, and urban or rural category. Results A total of 419 incident PD cases were identified (median [IQR] age, 73 [65-80] years; 257 male [61.3%]) with 5113 matched controls (median [IQR] age, 72 [65-79] years; 3043 male [59.5%]; 4504 White [88.1%]). After adjusting for patient demographics and neighborhood characteristics, living within 1 mile of a golf course was associated with 126% increased odds of developing PD compared with individuals living more than 6 miles away from a golf course (adjusted odds ratio [aOR], 2.26; 95% CI, 1.09-4.70). Individuals living within water service areas with a golf course had nearly double the odds of PD compared with individuals in water service areas without golf courses (aOR, 1.96; 95% CI, 1.20-3.23) and 49% greater odds compared with individuals with private wells (aOR, 1.49; 95% CI, 1.05-2.13). Additionally, individuals living in water service areas with a golf course in vulnerable groundwater regions had 82% greater odds of developing PD compared with those in nonvulnerable groundwater regions (aOR, 1.82; 95% CI, 1.09-3.03). Conclusions and Relevance In this population-based case-control study, the greatest risk of PD was found within 1 to 3 miles of a golf course and risk generally decreased with distance. Associations with the largest effect sizes were in water service areas with a golf course and in vulnerable ground water regions.